The Genmab (CPSE:GMAB) biotech firm recently experienced some fluctuation in its share price, necessitating numerous valuation checks. The company's performance drew the attention of different bodies, with Guggenheim lowering their stock price target following weak guidance, while H.C. Wainwright raised theirs because of promising pipeline strength. In recent times, Genmab increased its share capital after employee warrant exercises while simultaneously executing a DKK 725m share buy-back program. The company anticipates a 19% revenue growth to $3.7B by 2025 courtesy of proprietary medicine sales. Furthermore, Deutsche Bank sees potential oncology upside for these shares.
Genmab also recently received an FDA Breakthrough for Rina-S and announced the initiation of a share buy-back program. Their acquisition of Merus for $8bn is said to expand their late-stage pipeline and fast-track their move towards a wholly-owned model. Genmab’s pricing appears undervalued according to some analysts despite robust demand for Darzalex driving growth. Various financial investing bodies have raised their stock price targets for Genmab based on its positive developments and projected potential. Despite some challenges in Q4, the company's growth remains on an optimistic trajectory.
Genmab Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 28 Feb 2026 12:09:44 GMT - Rating 6 - Innovation 5 - Information 7 - Rumor 4
